AN2 Therapeutics, Inc.
NASDAQ:ANTXBiotechnology
+$0.04 today
- Market cap
- $187.82M
- Beta
- -0.98
- P/E (TTM)
- -4.9
- EPS (TTM)
- -$1.01
Volume 0.97M
Average 0.29M
ANTX Interest Income
Income earned on cash, deposits, and investments held by the company.
AN2 Therapeutics, Inc.NASDAQ: ANTX
Interest Income · Q1 FY2026 · quarter ended Mar 2026
Interest income declines year over year
Q1 FY2026 interest income of $523K fell 41.1% year over year, behind the -28.6% change in trailing-twelve-month interest income. Sequentially, it fell 13.6% from the prior quarter. Over 3 fiscal years it compounded at +29.5% a year.
Context
- Interest income increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -41.1% toward the trailing-twelve-month pace of -28.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Interest Income history
USD · from the income statement
- Latest · FY2025
- 2.93M USD
- Year-over-year change
- -46.3%
- 4-year CAGR
- +155.4%
| Period | Period end | Interest Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.93M | -46.3% |
| FY2024 | 2024-12-31 | 5.47M | +12.5% |
| FY2023 | 2023-12-31 | 4.86M | +259.7% |
| FY2022 | 2022-12-31 | 1.35M | +1858.0% |
| FY2021 | 2021-12-31 | 69K | — |
Interest Income vs competitors
How ANTX compares with its peers on the latest reported figures
- ANTX's LTM Mar 2026 interest income of $2.57M is the 3rd highest of the 6 companies compared; the peer median is $2.15M.
- Its year-over-year change of -28.6% is the 3rd highest of 6, against a peer median of -31.4%.
- Over three fiscal years its annual growth of +29.5% compares with a peer median of +100.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $4.69M | -41.8% | +100.2% | — | |
| LTM Jun 2026 | $4.11M | +739.9% | +172.1% | — | |
| LTM Mar 2026 | $2.57M | -28.6% | +29.5% | — | |
| LTM Jun 2026 | $2.15M | +392.0% | +116.1% | 2150.0% | |
| LTM Mar 2026 | $1.5M | -78.2% | -12.0% | 2.8% | |
| LTM Mar 2026 | $793K | -31.4% | +25.0% | 2.1% | |
| Peer median (excluding ANTX) | $2.15M | -31.4% | +100.2% | 2.8% | |
Competitors are the stored peer set for ANTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 77K | 0 | 0 | 0 |
| Gross Profit | 0 | (77K) | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 16.91M | 29.51M | 54.87M | 40.49M | 24.77M |
| Selling, General & Admin | 4.67M | 12.75M | 14.76M | 14.07M | 13.34M |
| Operating Expenses | 21.57M | 42.19M | 69.64M | 54.55M | 38.11M |
| Depreciation & Amortization | 0 | 77K | 69.64M | 54.55M | 0 |
| EBITDA | (21.54M) | (40.88M) | 4.9M | 3.23M | (35.17M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (21.57M) | (42.26M) | (69.64M) | (54.55M) | (38.11M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 69K | 1.35M | 4.86M | 5.47M | 2.93M |
| Interest Expense | 0 | 514K | 0 | 0 | 0 |
| Other Income / Expenses | 31K | 1.31M | 4.9M | 3.23M | 2.94M |
| Income Before Tax | (21.54M) | (40.96M) | (64.73M) | (51.32M) | (35.17M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (21.54M) | (40.96M) | (64.73M) | (51.32M) | (35.17M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.50) | (2.79) | (2.74) | (1.72) | (1.16) |
| EPS (Diluted) | (1.50) | (2.79) | (2.74) | (1.72) | (1.16) |
| Weighted Avg Shares | 18.74M | 15.34M | 23.6M | 29.83M | 30.22M |
| Weighted Avg Shares (Diluted) | 18.74M | 15.34M | 23.6M | 29.83M | 30.22M |
AN2 Therapeutics, Inc.
NASDAQ:ANTX
Intrinsic Alpha fair value
Locked
Current Price
$4.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.